1.Sales and profit
See section β- BridgeBio Oncology Therapeutics, Inc. lost $134M in fiscal 2025.
BridgeBio Oncology Therapeutics, Inc.
BBOT Nasdaq Pharmaceutical Preparations Financials FY2023βFY2025
Download report
3-page PDF: the company, its results and charts with peers.
Last close Β· Oct 23, 2026
$2.66
6.7%
Charts by
KIRAβs summary AI analyst
Hi! I read BridgeBio Oncology Therapeutics, Inc.βs latest annual report (fiscal 2025). Here is what stands out:
2 to watch
2.Cash and shareholders
See section β- Free cash flow was β$115M in fiscal 2025, β of revenue.
- No open-market insider trades in the last 12 months.
BridgeBio Oncology Therapeutics, Inc. in 30 seconds
Good So-so Weak
Weak
Does it make a profit?
β$134M
No. It lost money last year.
For information
How is the share priced?
β
No P/E: it made no profit over the last four quarters.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Key numbers, fiscal 2025
Market cap
Last close times the latest diluted share count, so it is approximate.
$213M
Oct 23 close
P/E
Last close divided by diluted earnings per share over the last four quarters.
β
On β$614.92 EPS (TTM)
Sales and profit
Is it selling more, and how much does it keep?
Results dates
In plain words: Every quarter, companies publish how much they sold and earned. These are the days BridgeBio Oncology Therapeutics, Inc. did it, and the next one. Share prices often move a lot on those days.
Next results
November 11, 2026
Wednesday Β· in 17 days
- Time
- Time not announced
- Covers
- Period ended Sep 30, 2026
- Expected EPS
- β$0.65
- Source
- Earnings calendar
No past results dates on file yet.
Revenue and margins
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
FY23
Revenue β
FY24
Revenue β
FY25
Revenue β
FY23
Gross β
Operating β
Net β
FCF β
FY24
Gross β
Operating β
Net β
FCF β
FY25
Gross β
Operating β
Net β
FCF β
Gross
Operating
Net
FCF
Net income and earnings per share
KIRA Β· BridgeBio Oncology Therapeutics, Inc. lost $134M in fiscal 2025.
Loss periods are shown in red.
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
FY23
Net income β$0.0M
FY24
Net income β$74.3M
FY25
Net income β$134M
Q1 '24
Net income β$15.4M
Q2 '24
Net income β$21.8M
Q3 '24
Net income β$17.3M
Q4 '24
Net income β$19.7M
Q1 '25
Net income β$22.1M
Q2 '25
Net income β$28.4M
Q3 '25
Net income β$44.8M
Q4 '25
Net income β$38.8M
Q1 '26
Net income β$42.1M
Q2 '26
Net income β$56.5M
FY23
Diluted EPS β
FY24
Diluted EPS β$5,756.41
FY25
Diluted EPS β$4.30
Q1 '24
Diluted EPS β
Q2 '24
Diluted EPS β
Q3 '24
Diluted EPS β$1,562.18
Q4 '24
Diluted EPS β
Q1 '25
Diluted EPS β$54.23
Q2 '25
Diluted EPS β$566.46
Q3 '25
Diluted EPS β$1.03
Q4 '25
Diluted EPS $617.42
Q1 '26
Diluted EPS β$526.11
Q2 '26
Diluted EPS β$705.20
Cash and shareholders
How much cash comes in, and where does it go?
Cash flow
KIRA Β· Free cash flow was β$115M in fiscal 2025, β of revenue.
Cash from operations minus capital spending.
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
FY23
Free cash flow β
FY24
Free cash flow β$55.1M
FY25
Free cash flow β$115M
Q1 '24
Free cash flow β
Q2 '24
Free cash flow β
Q3 '24
Free cash flow β
Q4 '24
Free cash flow β$15.0M
Q1 '25
Free cash flow β$19.8M
Q2 '25
Free cash flow β$23.5M
Q3 '25
Free cash flow β$28.9M
Q4 '25
Free cash flow β$42.3M
Q1 '26
Free cash flow β$35.9M
Q2 '26
Free cash flow β$44.4M
FY23
Cash from operations β
Capital spending β
FY24
Cash from operations β$55.0M
Capital spending $0.0M
FY25
Cash from operations β$114M
Capital spending $0.6M
Cash from operations
Capital spending
Q1 '24
Cash from operations β$0.6M
Capital spending β
Q2 '24
Cash from operations β$0.0M
Capital spending β
Q3 '24
Cash from operations β$39.3M
Capital spending β
Q4 '24
Cash from operations β$15.0M
Capital spending $0.0M
Q1 '25
Cash from operations β$19.6M
Capital spending $0.2M
Q2 '25
Cash from operations β$23.3M
Capital spending $0.2M
Q3 '25
Cash from operations β$28.8M
Capital spending $0.1M
Q4 '25
Cash from operations β$42.2M
Capital spending $0.1M
Q1 '26
Cash from operations β$35.9M
Capital spending $0.0M
Q2 '26
Cash from operations β$44.4M
Capital spending $0.0M
Cash from operations
Capital spending
Dividends, buybacks and share count
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
FY23
Dividends β
Buybacks β
FY24
Dividends β
Buybacks β
FY25
Dividends β
Buybacks β
Dividends
Buybacks
FY23
Diluted shares β
FY24
Diluted shares 0.00B
FY25
Diluted shares 0.03B
Insider trades
KIRA Β· No open-market insider trades in the last 12 months.
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
No open-market insider trades in the last 12 months.
Financial health
Can it carry its debts, and how well does it use its money?
Balance sheet
Cash, debt and the ratios that show how comfortably BridgeBio Oncology Therapeutics, Inc. can carry it.
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
FY23
Cash $0.3M
Debt β
FY24
Cash $156M
Debt β
FY25
Cash $425M
Debt β
Cash
Debt
| Fiscal year end | FY23 | FY24 | FY25 |
|---|---|---|---|
| Cash and short-term investments | $0.3M | $156M | $425M |
| Current ratio | β | 8.1x | 12.3x |
| Quick ratio | β | 8.1x | 12.3x |
| Total assets | $0.3M | $164M | $448M |
| Total liabilities | $0.4M | $19.6M | $37.3M |
| Shareholders' equity | β$116M | β$179M | $411M |
| Net debt (β = net cash) | β | β | β |
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
FY23
Return on capital β
Return on equity β
Return on assets β12.5%
FY24
Return on capital β
Return on equity β
Return on assets β90.2%
FY25
Return on capital β
Return on equity β115.3%
Return on assets β43.8%
Return on capital
Return on equity
Return on assets
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | β | β | β |
| Cash from operations is positive | β | β | β |
| Return on assets rose | β | β | β |
| Cash from operations exceeds net income | β | β | β |
| Debt fell relative to assets | β | β | β |
| Current ratio rose | β | β | β |
| Share count didn't rise | β | β | β |
| Gross margin rose | β | β | β |
| Revenue rose relative to assets | β | β | β |
| F-score | β / 1 | β / 4 | β / 6 |
| Accruals ratio | β | β23.4% | β6.6% |
| Altman Z'' | β | β11.75 | 12.61 |
All figures
Every number, year by year.
3 years of figures
Amounts in USD. Hover a ratioβs name for its definition.
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
| Fiscal year | FY23 | FY24 | FY25 |
|---|---|---|---|
| Income statement | |||
| Research and development | β | $73.1M | $121M |
| Operating income | β$0.0M | β$80.9M | β$146M |
| Income tax | β | $0.0M | $0.0M |
| Net income | β$0.0M | β$74.3M | β$134M |
| Diluted EPS | β | β$5,756.41 | β$4.30 |
| Diluted shares | β | 0.00B | 0.03B |
| Cash flow | |||
| Cash from operations | β | β$55.0M | β$114M |
| Capital expenditure | β | $0.0M | $0.6M |
| Free cash flow | β | β$55.1M | β$115M |
| Depreciation and amortization | β | $0.2M | $0.3M |
| Stock-based compensation | β | $4.4M | $5.9M |
| Balance sheet | |||
| Cash and short-term investments | $0.3M | $156M | $425M |
| Current assets | β | $159M | $432M |
| Current liabilities | $0.4M | $19.6M | $35.0M |
| Property and equipment, net | β | $0.5M | $1.0M |
| Total assets | $0.3M | $164M | $448M |
| Total liabilities | $0.4M | $19.6M | $37.3M |
| Shareholders' equity | β$116M | β$179M | $411M |
| Returns | |||
| Return on capital employed | 65.6% | β55.9% | β35.3% |
| Return on equity | β | β | β115.3% |
| Return on assets | β12.5% | β90.2% | β43.8% |
| Return on tangible equity | β | β | β32.6% |
| Growth | |||
| Share count change | β | β | 241,332.6% |
| Financial health | |||
| Current ratio | β | 8.1x | 12.3x |
| Quick ratio | β | 8.1x | 12.3x |
| Quality scores | |||
| Altman Z'' | β | β11.7 | 12.6 |
| Accruals ratio | β | β23.4% | β6.6% |
Source: SEC EDGAR XBRL filings (CIK 0001869105). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.